Gefitinib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<applet load="" size=" | <applet load="" size="350" color="" frame="true" spin="on" Scene ="Gefitinib/Gefitinib/1" align="right" caption="Gefitinib, also known as Iressa"/> | ||
===Better Known as: Iressa=== | ===Better Known as: Iressa=== | ||
* Marketed By: AstraZeneca & Teva | * Marketed By: AstraZeneca & Teva | ||
* Major Indication: Pancreatic & Small | * Major Indication: Pancreatic & Small Cell Lung [[Cancer]] | ||
* Drug Class: [[EGFR]] Inhibitor | * Drug Class: [[EGFR]] Inhibitor | ||
* Date of FDA Approval (Expiration): 2003 (2013) | * Date of FDA Approval (Expiration): 2003 (2013) | ||
